JERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new ...

The considerable ownership by individual investors in Entera Bio indicates that they collectively have a greater say in management and business strategy 45% of the business is held by the top 25 ...

Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex ®, the Only Approved GLP-2 Therapy Oral GLP-2 Tablet Could Transform ...

JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business ...

Entera Bio shares climbed after the company said the U.S. Food and Drug Administration agreed with the company's proposal that bone mineral density be the primary endpoint for a phase 3 study in ...

JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response ...

OPKO Health, Inc. (NASDAQ:OPK) is one of the Best American Penny Stocks to Buy According to Analysts. On July 8, OPKO Health, Inc. (NASDAQ:OPK) in collaboration with Entera Bio Ltd. (NASDAQ: ENTX) ...

Entera Bio ( (ENTX)) has released its Q2 earnings. Here is a breakdown of the information Entera Bio presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...

MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo ...